A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)

LESSONS LEARNED: Apatinib has potential as an effective and safe second‐line or higher treatment for patients with chemotherapy‐refractory esophageal squamous cell carcinoma (ESCC). Clinical safety is of potential concern when administering apatinib to patients with uncontrolled esophageal lesions o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Chu, Li, Chen, Yun, Liu, Qi, Liang, Fei, Wang, Shengping, Liu, Quan, Yu, Hui, Wu, Xianghua, Zhang, Junhua, Deng, Jiaying, Ai, Dashan, Zhu, Zhengfei, Nie, Yongzhan, Zhao, Kuaile
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2021
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176978/
https://ncbi.nlm.nih.gov/pubmed/33393167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13668
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars